 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for IRX5 |
 Gene summary |
| Basic gene information | Gene symbol | IRX5 |
| Gene name | iroquois homeobox 5 | |
| Synonyms | HMMS|IRX-2a|IRXB2 | |
| Cytomap | UCSC genome browser: 16q12.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001252197.1, NM_005853.5, | |
| Description | homeodomain protein IRX-2Ahomeodomain protein IRXB2iroquois-class homeodomain protein IRX-5 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 606195 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000176842 | ||
| HPRD : 08395 | ||
| Vega : OTTHUMG00000133201 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_IRX5 | |
| BioGPS: 10265 | ||
| Pathway | NCI Pathway Interaction Database: IRX5 | |
| KEGG: IRX5 | ||
| REACTOME: IRX5 | ||
| Pathway Commons: IRX5 | ||
| Context | iHOP: IRX5 | |
| ligand binding site mutation search in PubMed: IRX5 | ||
| UCL Cancer Institute: IRX5 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | BreastLung | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | BRCALUAD,LUSC | |
| Reference showing the relevant tissue of IRX5 | ||
| Description by TissGene annotations | ||
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for IRX5 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| THCA | -3.993181003 | -5.018755579 | 1.025574576 | 2.20E-07 | 9.19E-07 |
| BRCA | 3.437336095 | 2.41892206 | 1.018414035 | 2.12E-10 | 8.17E-10 |
| KICH | -3.910310291 | 1.093929709 | -5.00424 | 9.82E-19 | 5.28E-17 |
| COAD | -2.977222137 | -5.484956753 | 2.507734615 | 3.44E-07 | 2.15E-06 |
| LIHC | -3.671166291 | -5.304306291 | 1.63314 | 4.69E-06 | 2.15E-05 |
| Top |
| TissGene-miRNA for IRX5 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for IRX5 |
| TissGeneSNV for IRX5 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.P254T | COAD | 2 |
| p.R117Q | STAD | 1 |
| p.A103V | COAD | 1 |
| p.V327L | READ | 1 |
| p.Y415C | ESCA | 1 |
| p.T413M | CESC | 1 |
| p.P204S | STAD | 1 |
| p.L157V | LUAD | 1 |
| p.V160A | STAD | 1 |
| p.P391L | LUSC | 1 |
| p.A406S | SARC | 1 |
| p.A104V | HNSC | 1 |
| p.E186K | UCEC | 1 |
| p.G419E | HNSC | 1 |
| p.S344L | SKCM | 1 |
| p.L370P | SKCM | 1 |
| p.G441A | BLCA | 1 |
| p.K210E | COAD | 1 |
| p.P390S | SKCM | 1 |
| p.A124T | LUSC | 1 |
| p.S437C | BLCA | 1 |
| p.L460S | UCEC | 1 |
| p.A94V | ESCA | 1 |
| p.P391S | SKCM | 1 |
| p.H438Y | BLCA | 1 |
| p.A77T | STAD | 1 |
| p.R400W | BLCA | 1 |
| p.R182W | UCEC | 1 |
| p.L402V | BLCA | 1 |
| p.E217K | BLCA | 1 |
| p.L128V | ESCA | 1 |
| p.A94S | COAD | 1 |
| p.P254T | READ | 1 |
| p.D70H | HNSC | 1 |
| p.S19L | BLCA | 1 |
| p.P358S | SKCM | 1 |
| p.M155V | SKCM | 1 |
| p.E188K | ESCA | 1 |
| p.Q465* | SKCM | 1 |
| p.D187N | BLCA | 1 |
| p.E201K | STAD | 1 |
| p.D471N | HNSC | 1 |
| p.E197Q | ESCA | 1 |
| p.P391A | LUAD | 1 |
| p.G441V | KIRC | 1 |
| p.Y23H | STAD | 1 |
| p.H100Y | SKCM | 1 |
| p.L371P | SKCM | 1 |
| p.D34N | HNSC | 1 |
| p.H438R | UCEC | 1 |
| p.P360L | STAD | 1 |
| p.H419Y | COAD | 1 |
| p.P435L | STAD | 1 |
| p.P213R | LIHC | 1 |
| p.G419V | THYM | 1 |
| p.P213L | LGG | 1 |
| p.R136H | STAD | 1 |
| p.T178P | SKCM | 1 |
| p.R384G | LUAD | 1 |
| p.K206R | LIHC | 1 |
| p.S29L | BLCA | 1 |
| p.Q464X | SKCM | 1 |
| p.T125M | BLCA | 1 |
| p.P15L | SKCM | 1 |
| p.G364E | LGG | 1 |
| p.P21S | UCEC | 1 |
| Top |
| TissGeneCNV for IRX5 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for IRX5 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for IRX5 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| IRX5, APLF (tumor) | IRX5, APLF (normal) |
 |  |
| Top |
| TissGeneProg for IRX5 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for IRX5 |
| TissGeneDrug for IRX5 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for IRX5 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0000768 | Congenital Abnormality | 1 | BeFree |
| umls:C0001430 | Adenoma | 1 | BeFree |
| umls:C0007102 | Malignant tumor of colon | 1 | BeFree |
| umls:C0018784 | Sensorineural Hearing Loss (disorder) | 1 | CTD_human |
| umls:C0018798 | Congenital Heart Defects | 1 | CTD_human |
| umls:C0022904 | Lacrimal Apparatus Diseases | 1 | CTD_human |
| umls:C0024115 | Lung diseases | 1 | CTD_human |
| umls:C0027092 | Myopia | 1 | CTD_human |
| umls:C0033578 | Prostatic Neoplasms | 1 | LHGDN |
| umls:C0271901 | Microcytic hypochromic anemia (disorder) | 1 | CTD_human |
| umls:C0376358 | Malignant neoplasm of prostate | 1 | BeFree |
| umls:C0376634 | Craniofacial Abnormalities | 1 | CTD_human |
| umls:C0399352 | Developmental absence of tooth | 1 | CTD_human |
| umls:C0525041 | Neurobehavioral Manifestations | 1 | GAD |
| umls:C0600139 | Prostate carcinoma | 1 | BeFree |
| umls:C0699790 | Colon Carcinoma | 1 | BeFree |
| umls:C1876203 | Frontonasal dysplasia | 1 | CTD_human |
| umls:C1970027 | Hypertelorism, Severe, With Midface Prominence, Myopia, Mental Retardation, And Bone Fragility | 1 | CLINVAR,ORPHANET,UNIPROT |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |